Valuation: Virbac

Market Cap 282.46Cr 317.76Cr 261.8Cr 238.2Cr 449.48Cr 30TCr 456.69Cr 3.15TCr 1.23TCr 16TCr 1.19TCr 1.17TCr 50TCr P/E 2026 *
16.3x
P/E 2027 * 14.7x
Enterprise Value 294.7Cr 331.53Cr 273.15Cr 248.52Cr 468.96Cr 31TCr 476.48Cr 3.28TCr 1.29TCr 16TCr 1.24TCr 1.22TCr 52TCr EV / Sales 2026 *
1.9x
EV / Sales 2027 * 1.75x
Free-Float
49.03%
Yield 2026 *
0.53%
Yield 2027 * 0.63%
1 day+0.15%
1 week+6.14%
Current month+8.19%
1 month+7.15%
3 months+3.37%
6 months-12.13%
Current year-5.73%
1 week 316
Extreme 316
339.5
1 month 301
Extreme 301
339.5
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
448.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Date Insider Type Main position Quantity % Market Cap. Importance
22/04/24 Sell

Chief Executive Officer

810 0.0096%
22/04/24 Sell

Chief Executive Officer

140 0.0017%
22/04/24 Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+6.14%+1.05%+29.37% 317.76Cr
+0.43%+6.59%+56.57%+106.64% 1,12000Cr
+0.90%-2.25%+32.26%+63.73% 62TCr
+0.71%+3.24%+24.33%+91.33% 50TCr
-0.13%+5.98%+33.66%+50.18% 37TCr
+0.52%+0.24%+72.13%+40.11% 36TCr
-0.95%+4.70%+19.65%+42.71% 29TCr
-1.98%+3.73%-0.89%+10.43% 26TCr
-0.35%+4.25%+44.74%+52.06% 23TCr
-0.75%+3.32%+27.18%+94.07% 19TCr
Average -0.14%+3.87%+31.07%+58.06% 39.44TCr
Weighted average by Cap. +0.13%+3.83%+39.31%+71.79%

Financials

2026 *2027 *
Net sales 155.12Cr 174.51Cr 143.78Cr 130.81Cr 246.84Cr 17TCr 250.8Cr 1.73TCr 677.6Cr 8.64TCr 654.93Cr 640.98Cr 28TCr 164.43Cr 184.98Cr 152.4Cr 138.66Cr 261.66Cr 18TCr 265.85Cr 1.83TCr 718.26Cr 9.16TCr 694.23Cr 679.45Cr 29TCr
Net income 17Cr 20Cr 16Cr 15Cr 28Cr 1.86TCr 28Cr 194.39Cr 76Cr 972.15Cr 74Cr 72Cr 3.1TCr 19Cr 22Cr 18Cr 16Cr 31Cr 2.07TCr 31Cr 215.84Cr 85Cr 1.08TCr 82Cr 80Cr 3.44TCr
Net Debt 12Cr 14Cr 11Cr 10Cr 19Cr 1.31TCr 20Cr 136.36Cr 53Cr 681.95Cr 52Cr 51Cr 2.17TCr 4.47Cr 5.03Cr 4.14Cr 3.77Cr 7.12Cr 477.46Cr 7.23Cr 50Cr 20Cr 249.16Cr 19Cr 18Cr 794.29Cr
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
16/26/16 €337.00 +0.15% 4,835
15/26/15 €336.50 +0.45% 7,702
14/26/14 €335.00 +3.08% 5,637
13/26/13 €325.00 +2.52% 6,812
12/26/12 €317.00 -0.16% 3,405
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
337.00EUR
Average target price
412.75EUR
Spread / Average Target
+22.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock